Shanghai Zhijiang Biotech has repurchased a total of 2.75M shares, costing nearly 57.87 million yuan for an employee stock ownership plan.

Log in to the Sina Finance App and search 【information disclosure】 to view more evaluation levels

On April 3, 2026, Shanghai Zhijiang Biotechnology Co., Ltd. (hereinafter referred to as “Shanghai Zhijiang Bio”) released a progress announcement on the third share repurchase through centralized bidding transaction in 2025, disclosing the company’s share repurchase status as of March 31, 2026. The announcement shows that the company has cumulatively repurchased 2.752883 million shares, accounting for 1.43% of the total share capital, with cumulative funds used of 57.867 million yuan, and the repurchase price range is 18.38 yuan/share to 23.49 yuan/share.

Review of the Repurchase Plan

According to the announcement, on October 15, 2025, Shanghai Zhijiang Bio held the 16th meeting of the fifth session of the board of directors, which approved the share repurchase plan. The initial disclosure date of the plan was October 17, 2025. The implementation period runs from October 15, 2025 to October 14, 2026. The total repurchase funds are expected to be 60 million yuan to 120 million yuan. The repurchased shares are intended to be used for an employee share ownership plan or equity incentives. The repurchase price shall not exceed 37.99 yuan/share (inclusive).

Latest Repurchase Progress

The announcement shows that in March 2026, through the trading system of the Shanghai Stock Exchange, the company repurchased a total of 687,449 shares by way of centralized bidding transactions, accounting for 0.36% of the company’s current total share capital of 192.1580 million shares. In that month, the highest transaction price for the share repurchase was 20.75 yuan/share, and the lowest was 18.38 yuan/share. The total funds paid were 13.3780 million yuan (excluding transaction expenses such as stamp duty and trading commissions).

As of March 31, 2026, the company’s cumulative share repurchase status is as follows:

The announcement emphasizes that this share repurchase complies with relevant laws and regulations and the company’s share repurchase plan. The company states that within the repurchase period, it will repurchase from time to time based on market conditions, and will promptly fulfill its information disclosure obligations.

Purpose of the Share Repurchase and Its Market Significance

The shares repurchased by Shanghai Zhijiang Bio are intended to be used for an employee share ownership plan or equity incentives. This move is generally interpreted by the market as the company’s confidence in its long-term development prospects, as well as a positive signal that the company will stabilize its core team and improve corporate governance efficiency through incentive mechanisms. Judging from the repurchase progress, the company has already used cumulative funds of 57.867 million yuan, which is close to the lower limit of 60 million yuan under the repurchase plan, and there is still some room for further repurchases.

Investors may continue to follow the company’s subsequent repurchase progress and the specific implementation of the employee share ownership plan or equity incentive plan.

Disclaimer: The market involves risks; investment requires caution. This article is automatically published by an AI large model based on third-party databases and does not represent Sina Finance’s views. Any information appearing in this article is for reference only and does not constitute personal investment advice. If there are discrepancies, please refer to the actual announcement. If you have any questions, please contact biz@staff.sina.com.cn.

Click to view the original announcement>>

Endless information, precise analysis—right on the Sina Finance App

Editor: Xiao Lang Express